BETTEN-AID SIMPLE HEARTBURN RELIEF
  • Your heartburn meds are killing you!
    • Top 5 Reasons Never to Take a Proton Pump Inhibitor
    • Heartburn Meds Tied to Higher Diabetes Risk
    • Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID‐19: a meta‐analysis
    • Reflux Drugs Tied to Bone Fractures in Children
    • Heartburn drugs linked to fatal heart and kidney disease, stomach cancer
    • Millions of Canadians using acid-reflux drugs for too long, risking health side-effects
    • Using friendly bacteria to treat Irritable Bowel Syndrome
    • Proton Pump Inhibitors: How to Deprescribe These Nutrient Robbers
    • Pneumonia Risk with PPI Use Continues Past One Year, Researchers Say
    • Acidity and Heartburn Medications May Up Risk Of Pneumonia In The Elderly
    • Babies Given Antibiotics or Antacids May Be More Likely to Have Allergies, Study Finds
    • Study Links Popular Heartburn Drugs to Esophageal Cancer
    • The Purple Pill in the Red Zone
    • PPIs Linked to Pancreatic Cancer, Death
    • Guidelines for Limiting Unnecessary Use of Proton Pump Inhibitors
    • Superbug’ may depend on calcium to multiply
    • Some heartburn drugs linked with higher risk of death
    • Probiotics, Enzymes to Support Gut Health
    • Infants prescribed antacids for reflux have increased risk of bone fractures
    • How reflux drugs could raise fracture risk in babies
    • Heartburn Meds: Do They Do More Harm Than Good?
    • Day after Super Bowl, 16 million stay home on 'Super Sick Day'
    • Heartburn Medication Linked to Increased Risk of First Time Stroke
    • The Use Of Common Drugs For Heartburn Now Linked To Developing Stroke, Study Finds
    • Could common heartburn drugs increase stroke risk?
    • Stomach Flu More Common in PPI Users
    • Proton Pump Inhibitors May Reduce Efficacy of Capecitabine
    • Do This One Easy Thing If You Want Garbage In Your Cells
    • Proton Pump Inhibitor Lawsuits Mount
    • Study: PPI Acid Reflux Drugs Overused in People with GI Bleeds
    • PPI Heartburn Drugs Linked to Brain Problems, Fluid Build Up
    • Should you be taking stomach-acid reducers?
    • Dementia
    • Mental Health >
      • One-third of US adults may unknowingly use medications that can cause depression
      • Stomach acid drugs may cause depression
    • Heart Disease >
      • Giving PPIs and Antibiotics Together May Disrupt Heart Rhythm
      • Study Shows Heartburn Drugs Increase Risk of Cardiovascular Complications
    • Increased Infections >
      • AH-CHOO! THESE MEDS LINKED WITH HIGHER ALLERGY RISK IN KIDS
      • Acid Suppression Drugs Linked to Gastrointestinal Infections
      • PPIs increase risk for hepatic encephalopathy, spontaneous bacterial peritonitis
    • Kidney Failure >
      • ASN: PPIs associated with increased risk of kidney disease
      • Proton Pump Inhibitors May Increase Risk for Kidney Disease
      • Proton Pump Inhibitor Drugs Linked To Silent Kidney Damage
      • Popular OTC Acid Reflux Medicines May Carry Substantial Negative Side Effects, Studies Show
    • Osteoporosis >
      • New Concerns over Suspected Link Between Nexium and Osteoporosis
  • What is Betten-Aid?
    • Tummy Trouble Is On The Rise Among Americans, Gastrointestinal Experts Say
  • Store
  • A new Paradigm in Acid Reflux.
  • Natural vs. Synthetic
  • National group wants cancer warning labels on acid reflux drugs

Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID‐19: a meta‐analysis


We read with interest the study by Luxenburger et al. [1] which reported that patients with coronavirus disease 2019 (COVID‐19) receiving proton pump inhibitors (PPIs) were at increased risk for the development of secondary infection and acute respiratory distress syndrome. Understandably, the use of PPIs may lead to excessive suppression of gastric acid, and thus leading to impaired eradication of ingested pathogens, which results in the increased risk of secondary infection reported in the study. However, the association between the use of PPIs and adverse clinical outcomes such as acute respiratory syndrome in patients with COVID‐19 is not expected, since previous in vitro study has demonstrated the ability for PPIs to inhibit the production of pro‐inflammatory cytokines, which is suggestive of their potential to dampen cytokine storm associated with COVID‐19 [2]. Since there have been few studies addressing the same issue, we aimed to perform a meta‐analysis to summarize the overall effect of PPI on the COVID‐19 associated adverse clinical outcomes.
​

We performed literature searches in PubMed, Google Scholar and medRxiv (preprint repository) databases, up to 5 September 2020, for studies evaluating the risk of adverse clinical outcomes among COVID‐19 patients with PPI use compared to nonuse of PPI, with the following keywords and their MeSH terms: ‘COVID‐19’, ‘proton pump inhibitor’ and ‘PPI’ without language restrictions. The inclusion criteria were studies that investigated the use of PPIs on the risk of adverse clinical outcomes in patients with COVID‐19 with reported adjusted measures of association. Each included article was independently evaluated by two authors (CSK and SSH) who extracted the study characteristics and measures of effect. The quality of included studies was evaluated with the Newcastle‐Ottawa Scale [3]. The outcome of interest was the development of any COVID‐19 associated adverse clinical outcomes. Adjusted odds ratios (ORs) and adjusted relative risks and their corresponding 95% confidence intervals (CIs) from each study were pooled in a random‐effects model of meta‐analysis using Meta XL, version 5.3 (EpiGear International, Queensland, Australia). The I2 statistic was performed to estimate the heterogeneity.
Five studies that corresponded to inclusion criteria with a total of 37 372 patients were included for our meta‐analysis [1, 4-6]. Study characteristics are depicted in Table 1. All studies included are deemed good quality with a Newcastle‐Ottawa Scale of 8. There was nonuniformity in the definition of the adverse clinical outcomes utilized across the five included studies. In the study by McKeigue et al. [5], the adverse clinical outcome was defined as an entry to critical care, death within 28 days, or a death certificate with COVID‐19 as an underlying cause. In the study by Ramachandran et al. [6], the adverse clinical outcome was defined as in‐hospital mortality or the requirement for mechanical ventilation. In the study by Lee et al. [4], we utilized the composite endpoint of requirement of oxygen therapy, intensive care unit admission, administration of invasive ventilation, or death to define the adverse clinical outcome. In both the studies by Luxenburger et al. [1] and by Li et al. [7], the adverse clinical outcome was defined as the development of secondary infection.

The pooled analysis of studies by McKeigue et al. [5], Ramachandran et al. [6] and Lee et al. [4] revealed a significantly increased odds for a severe or fatal course of COVID‐19 with the use of PPIs in COVID‐19 patients relative to nonuse of PPIs (Fig. 1; pooled OR = 1.46; 95% CI 1.34–1.60). The pooled analysis of studies by Luxenburger et al. [1] and by Li et al. [7] observed a significantly increased odds for development of secondary infections with the use of PPIs in COVID‐19 patients relative to nonuse of PPIs (pooled OR = 2.91; 95% CI 1.58–5.36). Since excessive suppression of gastric acid production by PPIs may lead to bacterial overgrowth in the gut, it may be that the increased risk of severe or fatal course of illness observed with the use of PPIs in COVID‐19 patients is also due to the development of secondary pneumonia. However, since the increased risk for a severe or fatal course of COVID‐19 was small as observed in the effect size of our pooled analysis, the decision to discontinue PPIs in COVID‐19 patients should be based on an individual risk‐benefit assessment. Nevertheless, our findings again serve as a reminder for clinicians to regularly review the continuing need for acid suppression in every patient with PPI use. Since the studies included are of retrospective design with limited heterogeneity, more prospective studies are required to substantiate our findings.


https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13183​

Powered by Create your own unique website with customizable templates.